Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 6Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia 3Urinary Bladder Neoplasms 2Sarcoma 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Glioblastoma 2Breast Neoplasms 2Tumor Virus Infections 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Recurrence 1Primary Myelofibrosis 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Pain 1Osteosarcoma 1Neoplasms, Plasma Cell 1

Interventions

pembrolizumab 7Nivolumab 4Carboplatin 4Taxes 3Paclitaxel 3Gene Expression Profiling 3rucaparib 2aflibercept 2Radiotherapy 2Polymerase Chain Reaction 2Leucovorin 2Irinotecan 2Interleukin-12 Subunit p35 2Fluorouracil 2Drug Therapy 2Capecitabine 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2veliparib 1trastuzumab deruxtecan 1tocilizumab 1selinexor 1olaparib 1liposomal doxorubicin 1eribulin 1entinostat 1dehydroftorafur 1cc-486 1cabozantinib 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Azacitidine × Genitourinary × Clear all
NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

Celgene

Phase 1 Completed
169 enrolled
GastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡